In December 1995, the first protease inhibitor was approved for use by people with HIV, the virus that causes AIDS. This was followed quickly by several other protease inhibitors gaining approval in early 1996. In June 1996, the first non-nucleoside reverse transcriptase inhibitor received approval. The impact of these new drug therapies on the longevity and progression of HIV disease has been dramatic. In 1995, the number of people with AIDS who died totaled 51,117; in 2000, this number was 15,245 (U.S. Centers for Disease Control and Prevention 2001) .
Today, HIV disease may be thought of as a moderately expensive chronic illness rather than as a catastrophically expensive fatal illness (Yeni et al. 2002) . Indeed, the diffusion of new and powerful drugs has fundamentally transformed the way people perceive the consequences of HIV disease (Aldridge, Dannielle, and Doyle 2002) . This transformation is reflected in both the type and frequency of the services received by HIV patients.
This study examines the utilization of hospital care in eight states (California, Colorado, Florida, Iowa, New Jersey, New York, Pennsylvania, and South Carolina) , and the cost of hospital care in six states (California, Colorado, Kansas, New Jersey, New York, and South Carolina) . The eight states in the utilization study account for 52% of all AIDS cases in the nation; the six states in the cost study account for 39% of all AIDS cases. Specifically, I examine the average cost per hospital admission and the average length of a hospital stay in 1996 and 2000. I then examine how the average cost per hospital stay and length of stay varied across these states in 2000, using multivariate regression analytic techniques that account for a variety of patient attributes in addition to a hospital's teaching status.
Background
In the early years of the HIV/AIDS epidemicthe early 1980s-hospital care accounted for the greater part of the cost of treating a patient with HIV disease. The first widely cited study of the cost of treating HIV disease, which estimated the lifetime cost to be $147,000, included only hospital costs; other costs were considered to be negligible (Hardy et al. 1986 ). This estimate was generated using an estimate of 167 hospital days of care over the lifetime of a patient and it reflects the early experience of AIDS patients at several large hospitals in New York City.
Subsequent estimates of the cost of treating people with HIV disease in the nation were lower. For example, a year after the study by Hardy and colleagues, Scitovsky and Rice published estimates of the cost of treating all people with HIV disease in the nation based on treatment patterns in San Francisco (Scitovsky and Rice 1987) . They estimated that the lifetime cost of treating an AIDS patient was less than one-half the estimate by Hardy and colleagues. To a large extent, this difference was due to the considerable difference in the use of hospital care between patients in New York City and those in San Francisco.
Moreover, the proportion of costs attributable to hospital care in the Scitovsky and Rice study was 76%. Many subsequent studies have revealed large differences in the use of hospital services by patients with HIV disease across geographic areas of the nation (HIV Capitation Risk Adjustment Conference Report 1997; Shapiro et al. 1999; Fasciano et al. 1998) . Even in the current era of highly active antiretroviral therapy (HAART), hospital care remains a significant contributor to the cost of treating people with HIV disease. Hospital costs accounted for 38% of the total cost of HIV care in 1998 .
Although it is important to understand how changes in clinical treatment have affected the utilization and costs of care received by people with HIV disease, it is difficult to obtain information about the care received by these individuals. Most studies have examined people with HIV disease who have received care at specific provider sites (Weissman et al. 1996; Moore and Bartlett 1996; Moore and Chaisson 1997) . Both the AIDS Cost and Service Utilization Survey (ACSUS) (Hellinger 1993 ) and the HIV Cost and Services Utilization Study (HCSUS) (Bozzette et al. 1998 ) sampled patients with HIV disease from lists provided by a sample of clinics, outpatient hospital facilities, and physician practices. Thus, previous studies have not provided information about the utilization of services by people who were receiving care at other sites in an area. Initial reports soon after the introduction of protease inhibitors suggested that hospital inpatient censuses declined markedly (Palella et al. 1998; Torres and Barr 1997) , and estimates from the HCSUS showed that inpatient costs also declined after 1996 . These reports pertained to the first year or two after the introduction of these new and potent drugs, and they indicated that HIV patients were less likely to be hospitalized with an opportunistic infection or other HIV-related condition (Ledergerber et al. 1999) . Other research also revealed that the diffusion of protease inhibitors and non-nucleoside reverse transcriptase inhibitors (referred to as HAART) decreased the utilization of hospital services and increased drug costs for two or three years after the diffusion of HAART (i.e., from 1996 through 1998) (Gebo et al. 1999; Keiser et al. 1999; Mole, Ockrim, and Holodniy 1999; Bozzette et al. 2001) . Two of these papers examined patients treated at Veterans Administration facilities using data from 1995 through 1997; one examined Medicaid patients treated at The Johns Hopkins University AIDS Service from 1995 through 1997, and one study interviewed a randomly selected sample of almost 3,000 patients several times between 1996 and 1998. These reports also found that increased drug costs were more than offset by reductions in the cost of inpatient and outpatient care, and that HAART had reduced the total cost of treating people with HIV disease. They also showed that people on HAART had lower levels of virus in their blood stream, had higher CD4þ cell counts (i.e., more active immune system responses), were less likely to succumb to opportunistic infections, and were living longer.
More recent studies indicate that treatment trends for people with HIV continue to change. Indeed, the treatment of HIV patients is a dynamic process that requires a frequent balancing act between the continuation of treatment designed to suppress the virus and its dangerous sequelae, and treatment interruptions designed to free the patient from the sometimes harsh side effects of antiretroviral treatment. Over the past three to four years, there have been changes in the number and type of antiretroviral drugs used to treat patients (non-nucleoside reverse transcriptase inhibitors are now commonly substituted for protease inhibitors). There also has been a slow recognition that drug therapy may be delayed until patients reach CD4þ cell counts below 350, though evidence is conflicting on this, and there has been an increase in use of treatment interruptions (Bozzette et al. 2003; Mellors and Montaner 2000; Krentz, Auld, and Gill 2003; Mocroft et al. 2003; Sendi and Gafni 20003; Lane and Neaton 2003) . There is also some new evidence suggesting that starting HAART early may be superior to later treatment, and that treatment interruptions may not assist patients in combating drug resistant strains of HIV (Palella et al. 2003; Hirschel 2003) .
The composition of people newly infected with HIV also has changed over the past several years. Today, more than one-half of newly infected individuals are black and more than onethird are women. Moreover, the number of people infected each year has remained relatively constant (about 40,000), while the number of deaths due to HIV disease has decreased significantly. Consequently, the number of people with HIV disease is increasing rapidly. In fact, the number of persons living with AIDS increased by more than 25% between and 2000 . (U.S. CDC 2001 .
Data
This study uses data from an Agency for Healthcare Research and Quality (AHRQ) database to identify all HIV-related hospital admissions in eight states. The eight states in our utilization study and the six in our cost study include both high-and low-prevalence states in various regions of the nation (U.S. CDC 2001).
Hospital discharge data were obtained from the Healthcare Cost and Utilization Project's (HCUP) State Inpatient Database (SID), which is maintained by the AHRQ. The HCUP is a federal/state/industry partnership to build a multistate health care data system, with data obtained from state governments and state hospital associations. The SID includes data on inpatient stays from all community hospitals. AHRQ secures the data from each statewide data organization and transforms each data set into a common format.
The average cost of a hospital admission was obtained by converting hospital charges to cost using a methodology developed by Friedman and the AHRQ (Friedman et al. 2002) . This methodology derives a hospital-specific all-payer inpatient cost-to-charge ratio by matching American Hospital Association (AHA) Survey data and Centers for Medicare and Medicaid Services (CMS) accounting database records.
Since teaching hospitals might provide more expensive care, I wanted to identify teaching hospitals in the data. The teaching status of each hospital was determined using one of two measures. The first is a dichotomous variable indicating whether the hospital was a member of the Council of Teaching Hospitals (COTH). In general, COTH membership implies that a hospital is a major teaching facility. The COTH was formed by the Association of American Medical Colleges (AAMC) in 1965, and the roughly 400 COTH member institutions educate about threequarters of the physician residents in the United States. In addition, these hospitals supply a vast array of specialized services to patients in a clinical setting designed to foster clinical research. The second variable measuring teaching status is a dichotomous variable indicating whether the hospital operates a residency program. HCUP researchers obtained this information from the American Medical Association.
Methods
After October 1994, the International Classification of Diseases, 9th Revision, Clinical Modifications (ICD-9-CM) system included only one code (042) for HIV disease and AIDS. This study employs a conservative algorithm for identifying hospitalized patients with HIV disease. Only those patients with a primary or secondary code diagnosis (most states include up to six secondary diagnoses) that includes 042 are identified as patients with HIV disease. Thus, patients who are infected with HIV but who are not identified as such are not included in this analysis.
In the most comprehensive study of the accuracy of diagnostic coding for people with HIV disease, it was determined that 97% of people with an HIV diagnosis on their hospital discharge abstract were infected with HIV (Rosenblum et al. 1993) . In that study, more than 7,000 hospital records of people in six states with diagnostic codes indicative of HIV disease were examined. The authors were able to determine whether or not an individual was HIV-infected using AIDS surveillance data from state health departments and a review of the medical charts.
I also found that the predictive accuracy of conditions related to HIV disease was low when there was no code for HIV infection. Specifically, I found that 38% of people who had pneumocystis carinii pneumonia (PCP) coded on their hospital abstract without listing a diagnosis of HIV actually had HIV infection, and that this percentage was 23% or lower for other HIV-related illnesses when the record did not include the code for HIV infection. Unfortunately, there is no information about the use of pharmaceuticals on the hospital abstract, so I was unable to identify people with HIV disease based on their use of specific drugs such as protease inhibitors, nucleoside reverse transcriptase inhibitors, or nonnucleoside reverse transcriptase inhibitors.
The unit of observation in this study is a hospital admission by a patient with HIV. The average length of a hospital admission was calculated by dividing the total number of hospital days for hospital admissions with a 042 diagnostic code by the associated number of hospital admissions. I used a negative binomial regression model to estimate the determinants of the length of a hospital stay. Negative binomial regression is appropriate when there is a discrete variable (such as the length of a hospital stay) where the mean is considerably less than the variance (i.e., when there is overdispersion). The linear normal multivariate regression model was used to estimate the determinants of hospital costs. The standard errors were corrected for clustering at the hospital level in both the negative binomial and linear normal multivariate regression models using generalized estimating equations (SAS/STAT User's Guide 1999).
Information about whether a state has an enhanced reimbursement rate for HIV hospitalizations or for managed care enrollees with HIV disease also is used in this study. New York state has, possibly, the most generous reimbursement system for HIV-related hospitalizations covered by Medicaid (State of New York 1997). In 1994, New York expanded its Medicaid hospital reimbursement methodology based on diagnosis-related groups (DRGs) to include DRGs for HIV-related admissions according to the provision of specific services (e.g., HIV with operating room procedure and major related diagnosis, tracheotomy for HIV infection, and HIV with ventilator or nutrition support). Prior to this time, reimbursement for HIV-related admissions was based entirely on a patient's diagnostic codes. The new system imparts a strong incentive for hospitals to provide procedures to people with HIV disease. Moreover, parts of California provide an enhanced rate to Medicaid managed care organizations that enroll people with HIV disease (Conviser, Gamliel, and Honberg 1998) . This incentive may increase the volume of services received by people with HIV disease because higher rates make individuals with HIV disease profitable, and plans may attract them by offering more services.
The study also employs information about whether a state has initiated a home and community-based waiver (HCBW) program. HCBW programs provide a host of services that are intended to reduce the frequency and duration of hospital stays. Sixteen states have initiated HCBW programs for people with HIV disease, including six of the eight states in our sample (California, Colorado, Florida, New Jersey, Pennsylvania, and South Carolina) (Cowart and Mitchell 1995; Merzel et al. 1992; Miller, Richmond, and Harrington 1999) . 1 Patients' insurance status was categorized as Medicare, Medicaid, private, self-pay, or other. Hospital ownership was categorized as government, for-profit, or non-governmental not-forprofit. Race was categorized as black, white, Hispanic, or other. The number of diagnoses was set equal to the total number of diagnoses including comorbid diagnoses at the time of hospitalization. Data on the number of persons living with AIDS in each state were obtained from CDC surveillance activities (U.S. CDC 2001).
Results
Table 1 presents descriptive statistics based on all eight states in the data set for the study variables in 1996 and 2000. Over the four years from 1996 to 2000, the average length of an HIV-related hospital stay fell from 10.1 days to 8.9 days. Moreover, the average age of a hospitalized patient with HIV disease rose from 38 to 41 years of age, and the average number of diagnoses for each patient rose from 6.5 to 6.8. These changes indicate that the average hospitalized patient with HIV disease was older and slightly sicker than four years earlier.
The sociodemographic profile of hospital patients with HIV disease changed appreciably from 1996 to 2000. In particular, the proportion of hospital patients who were black increased from 46% to 51% from 1996 to 2000, while the proportion of hospital patients who were white decreased from 31% to 26%. The magnitude of the change for this variable was similar across states (data not shown). In each of the eight states, the proportion of hospital patients who were black increased and the proportion who were white decreased.
Perhaps, the most important change in the characteristics of HIV-infected hospitalized patients was the large increase in the percentage of patients covered by Medicare (17% in 1996 and 24% in 2000) . The rise in the percentage covered by Medicare was accompanied by a decline in the percentages of patients covered by Medicaid and private insurance. The reduction in the proportion of patients listing Medicaid as the primary payer may reflect in large part the fact that many people with HIV disease have been surviving long enough to become eligible for Medicare under disability criteria. The law necessitates that a person be disabled continuously for five months before he or she can qualify for a disabled worker cash benefit; a further 24 months is necessary to meet the requirements to be eligible under Medicare. Thus, HIV patients must survive at least 29 months after they are determined to be disabled by a designated social service agency. Disability is defined as the incapability to partake in substantial productive endeavors by reason of any medically determinable physical or mental impairment that can be expected to result in death or to last for a continuous period of not less than 12 months. Even though many Medicare patients may be Medicaid eligible, they are coded as Medicare in the HCUP database because Medicare is the primary payer. There is a field for secondary payer on hospital discharge abstracts, but it is not consistently filled out by all hospitals. Table 2 reveals a sharp reduction in the number of hospital admissions by HIV patients (114,885 in 1996 and 77,694 in 2000) and an increase in the number of persons living with AIDS (131,718 in 1996 and 167,948 in 2000) in the eight sample states. Each state experienced both a decrease in the number of HIV-related hospitalizations and an increase in the number of people with AIDS over the four years from 1996 to 2000. However, the rates of change varied across states. For example, Florida experienced a relatively small decrease in its number of HIV-related hospital admissions compared to the other seven states (11% in Florida compared to a 33% average decline for all eight states), even though its increase in the number of people with AIDS was roughly equivalent to the increase for all eight states (increase in Florida was 26% and for all eight states was 27%). Table 3 presents the average lengths of a hospital stay in the eight states in 1996 and 2000. Among people hospitalized with HIV, those in New York had the longest average hospital stay (12.4 days in 1996 and 10 days in 2000). Neighboring states did not exhibit uniformly high average lengths of stay. The average length of stay in New Jersey was relatively high, but the average length of stay for Pennsylvania was relatively low. The shortest length of stay in both 1996 and 2000 was found in Colorado, where patients with HIV disease were hospitalized for an average of 6.0 days in 1996 and 6.3 days in 2000. Three other states had an average length of hospital stay below eight days in 2000. Table 4 presents the results of a negative binomial regression equation explaining variations in a patient's length of stay. This regression included variables measuring: payer status (Medicare, Medicaid, private, other payer, self-pay, and nopay), race/ethnicity (white, black, Hispanic, and other), gender, age, number of diagnoses, hospital teaching status (member of COTH), hospital ownership (government, private not-for-profit, and private for-profit), the hospital's number of HIV-related admissions, and dummy variables for each state. Table 4 , which includes state-specific dichotomous variables, reveals that: all states have a shorter length of stay than New York; that black and Hispanic patients have longer lengths of stay than white patients; that Medicare and Medicaid patients have shorter lengths of stay than privately insured patients; that a greater number of diagnoses is associated with longer lengths of stay; and that men are hospitalized for longer periods of time than women. After adjusting for many factors that affect a hospital length of stay, the finding that the hospital stay is one and two-thirds days less in California, one day less in New Jersey, two days less in Florida and Pennsylvania, and about three days less in Colorado is notable. Indeed, Table 4 reveals that the state in which an HIV patient is hospitalized is a more important determinant of the length of stay than age, race, gender, insurance status, number of diagnoses, hospital ownership type, and hospital teaching status. The scaled deviance and the scaled Pearson chi-square have limiting chi-square distributions under certain regularity conditions and may be used as goodness of fit measures (SAS/STAT User's Guide 1999). These statistics are reported in Table 4 and indicate that this model is a good fit.
The mean of the cost of a hospital stay for the six states for which there was cost data was $15,037, and the mean of the charges of a hospital stay for these states was $28,055. The difference between the level of cost and charges indicates that the average hospital-specific all-payer inpatient cost-to-charge ratio was 54% across all hospitals in the six states. Table 5 presents estimates of the impact of a variety of factors on the average cost per hospital admission for patients with HIV disease in the Table 5 illustrates that the state in which an HIV patient receives hospital care is the most important determinant of the cost of a hospital stay even after adjusting the cost for a variety of other factors. In Model 1 (which includes a measure of the length of stay), I also found that the cost of a hospital visit for an HIV patient in California was $2,979 less than for a similar patient in New York, and that the cost was $2,942 less for HIV patients in New Jersey than for similar HIV patients in New York. Model 2 does not include a length of stay variable, and the estimated effect of being in Colorado was much greater. This is related to the fact that the average length of stay in Colorado was 37% lower than the length of stay in New York (the reference state).
Limitations of the Data
This study has a number of limitations. First, the findings are biased to the extent that the differences between the flow of patients with HIV disease into a state and the flow out of the state are significantly different. This study combines data on the number of people with AIDS in each state with information about the utilization of services in hospitals. I am unable to identify specific individuals, and it is clear that some people in a state receive care in another state. Evidently, issues of inflow and outflow are less significant for large states such as New York, Colorado, and California, and are less significant for states whose population centers are located far from its borders (e.g., Colorado and Florida).
Second, it is possible that in states where people with HIV disease have the greatest access to and utilization of hospital services there is less access to and utilization of outpatient services. However, this suggests, for example, that people with HIV disease in New York have the least access to and utilization of outpatient services. Although this seems unlikely, an empirical examination of this hypothesis is left as a topic for future research.
Third, this study examines the utilization of hospital care in eight states, and the cost of hos-pital care in six of these states. It is certainly possible that the relationship between race/ethnicity and hospital utilization and outcomes may differ in states not examined in this study.
Discussion
Rapid changes in treatment strategy, 2 the increasing number of persons living with HIV disease, and the changing composition of newly infected people make it difficult for public health officials to plan for taking care of people with HIV. There is a need for good information.
Two of the more important consequences of the diffusion of new and effective drug therapies have been the increase in the number of people with HIV disease and the decrease in the frequency of hospitalization. The findings in this This study also found that the proportion of HIV hospital patients who were black climbed from 46% in 1996 to 51% in 2000. This is consistent with observations from a variety of studies indicating that black persons with HIV disease are less likely to receive new, expensive, anti-retroviral drugs than white patients with HIV disease (Palella et al. 1998; Moore et al. 1994) . This suggests that the limited access blacks have to protease inhibitors and non-nucleoside reverse transcriptase inhibitors is at least partly responsible for the relatively large increase in the proportion of hospital visits attributable to black individuals.
Final Remarks
Access to good information about how patients with HIV disease use health care resources including hospital services remains a prerequisite for planners and legislators to ensure that people with HIV disease receive an appropriate and efficient mix of health care services. Most people with HIV disease depend upon public sources to pay for services. Thus, it is important to have accurate information about the health care services utilized by people with HIV disease to ensure that patients have access to necessary services (Hellinger 1998) . Federal and state governments spent almost $18 billion in fiscal year 2002 on assistance to people with HIV disease, and the bulk of these funds was spent on providing health care services (Kates 2002) . This study suggests that decision makers must be careful in applying findings about the use and cost of care for HIV patients in states other than their own regardless of whether or not these states are within the same region of our nation. This study reveals that the state in which an HIV patient is hospitalized is an important determinant of the length of hospital stay even after adjusting for a patient's age, gender, insurance status, and number of diagnoses and for the hospital's ownership category and teaching status. This study also reveals that the cost of a hospital stay for HIV patients varies significantly across states even after accounting for the aforementioned patient and hospital characteristics.
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1 HCBW programs provide services such as a homemaker, a home health aide, personal care, respite care, private duty nursing, medical supplies, and adaptive equipment (Anderson and Mitchell 1997; Buchanan and Chakravorty 1997) .
2 The recent diffusion of new classes of drugs such as protease inhibitors and non-nucleoside reverse transcriptase inhibitors as well as the diffusion of tests to determine which drugs are likely to be most effective for a specific patient have changed how patients with HIV are treated.
